AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Danaher Corporation
Video analysis: DHR
All videosNo video analysis for this stock yet. Request one from our team.
News: DHR
Danaher Corporation $DHR Shares Acquired by Concurrent Investment Advisors LLC
Concurrent Investment Advisors LLC lifted its stake in shares of Danaher Corporation (NYSE: DHR) by 29.8% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,715 shares of the conglomerate's stock after acquiring an additional 2,691 shares during the period.
Continuum Advisory LLC Decreases Holdings in Danaher Corporation $DHR
Continuum Advisory LLC lowered its position in Danaher Corporation (NYSE: DHR) by 87.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 481 shares of the conglomerate's stock after selling 3,498 shares during the period. Continuum Advisory LLC's
Danaher Corporation $DHR Shares Sold by HB Wealth Management LLC
HB Wealth Management LLC cut its position in Danaher Corporation (NYSE: DHR) by 13.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,772 shares of the conglomerate's stock after selling 7,499 shares during the period. HB Wealth Management LLC's
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.
Ausdal Financial Partners Inc. Buys Shares of 2,452 Danaher Corporation $DHR
Ausdal Financial Partners Inc. purchased a new position in Danaher Corporation (NYSE: DHR) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,452 shares of the conglomerate's stock, valued at approximately $467,000. Several other institutional investors and hedge funds have also
315,789 Shares in Danaher Corporation $DHR Purchased by Bamco Inc. NY
Bamco Inc. NY purchased a new stake in shares of Danaher Corporation (NYSE: DHR) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 315,789 shares of the conglomerate's stock, valued at approximately $227,381,000. Several other hedge funds have also bought and sold shares
Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?
DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
Similar companies
-
Boston Scientific Corporation
BSX
·
New York Stock Exchange
Compare
-
Stryker Corporation
SYK
·
New York Stock Exchange
Compare
-
Thermo Fisher Scientific Inc.
TMO
·
New York Stock Exchange
Compare
-
Gilead Sciences, Inc.
GILD
·
NASDAQ
Compare
-
Amgen Inc.
AMGN
·
NASDAQ
Compare
-
Pfizer Inc.
PFE
·
New York Stock Exchange
Compare